|
KMID : 0624620220550110547
|
|
BMB Reports
2022 Volume.55 No. 11 p.547 ~ p.552
|
|
|
DN200434, an orally available inverse agonist of estrogen-related receptor γ, induces ferroptosis in sorafenib-resistant hepatocellular carcinoma
|
|
Kim Dong-Ho
Kim Mi-Jin
Kim Na-Young
Lee Seung-Hyeong
Byun Jun-Kyu
Yun Jae-Won
Lee Jae-Bon
Jin Jong-Hwa
Kim Ji-Na
Chin Jung-Wook
Cho Sung-Jin
Lee In-Kyu
Choi Yeon-Kyung
Park Keun-Gyu
|
|
|
Abstract
|
|
|
|
Sorafenib, originally identified as an inhibitor of multiple oncogenic kinases, induces ferroptosis in hepatocellular carcinoma (HCC) cells. Several pathways that mitigate sorafenib-induced ferroptosis confer drug resistance; thus strategies that enhance ferroptosis increase sorafenib efficacy. Orphan nuclear receptor estrogen-related receptor γ (ERRγ) is upregulated in human HCC tissues and plays a role in cancer cell proliferation. The aim of this study was to determine whether inhibition of ERRγ with DN200434, an orally available inverse agonist, can overcome resistance to sorafenib through induction of ferroptosis. Sorafenib-resistant HCC cells were less sensitive to sorafenib-induced ferroptosis and showed significantly higher ERRγ levels than sorafenib-sensitive HCC cells. DN200434 induced lipid peroxidation and ferroptosis in sorafenib-resistant HCC cells. Mechanistically, DN200434 increased mitochondrial ROS generation by reducing glutathione/glutathione disulfide levels, which subsequently reduced mTOR activity and GPX4 levels. DN200434-induced amplification of the antitumor effects of sorafenib was confirmed in a tumor xenograft model. The present results indicate that DN200434 may be a novel therapeutic strategy to re-sensitize HCC cells to sorafenib.
|
|
|
KEYWORD
|
|
|
DN200434, ERRγ, Ferroptosis, Hepatocellular carcinoma, Sorafenib
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|